|
|
Vaccine Detail
|
Prodencel |
| Vaccine Information |
- Vaccine Name: Prodencel
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: prostate cancer (PC)-specific antigen(s) (NCIT_C192174)
- Immunization Route: subcutaneous injection
- Description: This is an autologous dendritic cell (DC) vaccine targeting prostate cancer (PC)-specific antigen(s), with potential immunostimulatory and antineoplastic activities. Upon administration of prodencel, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against PC cells expressing the antigen(s), resulting in tumor cell lysis. (NCIT_C192174) The vaccine could help treat patients with metastatic castration-resistant prostate cancer (mCRPC) after novel androgen-deprived therapy and docetaxel chemotherapy failure. (NCT05533203)
|
| Host Response |
|
|
| References |
NCIT_C192174: Prodencel [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C192174]
NCT05533203: Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) [https://clinicaltrials.gov/study/NCT05533203]
|
|
